| Cas No.: | 1887014-12-1 |
| SMILES: | N#CC1=CC=C(N[C@H](C2=CC3=C(NC2=O)C=CC(Cl)=C3)C)C(N1C)=O |
| Formula: | C18H15ClN4O2 |
| M.Wt: | 354.79 |
| Purity: | >98% |
| Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: | Olutasidenib (FT-2102) is a highly potent, selective small molecule inhibitor of IDH1 mutations. Scientists use it in the research of human acute myeloid leukemia. To our delight, it has entered clinical research. In the phase 1/2 study, Olutasidenib is well tolerated both as a sing-treatment and in combination with azacitidine.Overall, Olutasidenib exhibits favorable safety and PK/PD. It inhibits IDH1 mutations in AML patients. Further study need to be done to explore more potential in the treatment of acute myeloid leukemia. |
MSDS
COA
| LOT NO. | DOWNLOAD |
|
|
|
| 2018-0101 |
|